Performance Period: 9/1/2020 to 8/31/2021
In the past decade, with the rapid development of cell therapies, the U.S. biopharmaceutical industry has made major advancements to cure some of society’s most devastating cancers and diseases. Unlike traditional or protein biopharmaceuticals, cell therapy manufacturing involves manipulating either the patient’s own cells – i.e. autologous therapy—or a donor’s cells– i.e. allogenic therapy—to fight the disease. Yet, advancements in the commercialization of treatments and establishing large-scale manufacturing has been impeded due to workforce shortages. Across the country, a lack of training programs that cater to incumbent workers in the cell therapy sector has slowed the workforce pipeline.
Working in concert with industry partners, Shoreline Community College (PI: Guy Hamilton) in partnership with Celgene Corporation (Co-PI: Snehal Patel), propose to create the Cell Therapy Incumbent Worker Training Program. To develop the program, Shoreline will convene a broad group of cell therapy companies to identify specific workforce gaps, challenges, and training needs. From those meetings, Shoreline will develop training materials and curriculum, and then pilot the training modules. Upon completion of the pilot, Shoreline will launch the training program and begin accepting trainees.
Increased efficiency and accuracy in cell therapy manufacturing, increased industry-wide awareness of cell therapies, increased capacity for companies to scale out the manufacturing process and decreased costs and amount of time for cell therapy companies
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Shoreline Community College